Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|WF-1801||NCORP-Wake Forest University||A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy||Cancer Prevention and Control CIRB||Available to Open|
|9608||ETCTN||A Phase I Trial of ABT-263 (Navitoclax); a Bcl-2 inhibitor; and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|CALGB-50303||CALGB||Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|D9902||COG||Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Colon, Kidney, Liver, Multiple Myeloma, and Prostate among Racially and Ethnically Diverse Populations||Pediatric CIRB||Available to Open|
|A031901||Alliance||Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA8184||ECOG-ACRIN||A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers||Cancer Prevention and Control CIRB||Available to Open|
|A031501||Alliance||Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation||Adult CIRB - Late Phase Emphasis||Available to Open|
|10296||ETCTN||Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive (HER2+) metastatic breast cancer (MBC) with PIK3CA mutation or PTEN mutation||Adult CIRB - Early Phase Emphasis||Available to Open|
|A151804||Alliance||Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-CC003||NRG||Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with Or without Hippocampal Avoidance for Small Cell Lung Cancer||Cancer Prevention and Control CIRB||Available to Open|